Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:00:35 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:BCLI - BRAINSTROM CELL THERAPEUTICS - https://www.brainstorm-cell.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BCLI - Qnot subscribed0.84-0.33-28.2819.75711,1600.70  0.8936  0.596.30  0.723315:59:59Jul 1715 min RT 2¢

Recent Trades - Last 10 of 1160
Time ETExPriceChangeVolume
15:59:59Q0.84-0.332,000
15:59:53Q0.87-0.30316
15:59:53Q0.87-0.30209
15:59:47Q0.87-0.304,000
15:59:47Q0.855-0.3154,000
15:59:18Q0.84-0.33245
15:59:11Q0.861-0.3091,000
15:59:07Q0.84-0.3337
15:58:55Q0.84-0.33234
15:58:37Q0.87-0.301,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-17 16:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
2025-07-08 07:00U:BCLINews ReleaseFDA Review of Citizen Petition Offers a Fresh Look at NurOwn(TM)'s Evidence of Treatment Effectiveness
2025-06-16 08:30U:BCLINews ReleaseBrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn(TM)
2025-05-27 07:00U:BCLINews ReleaseBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn(TM) Phase 3b ALS Clinical Trials
2025-05-19 07:00U:BCLINews ReleaseBrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(TM) for ALS
2025-05-15 16:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-15 07:30U:BCLINews ReleaseBrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
2025-05-07 06:30U:BCLINews ReleaseBrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
2025-05-06 07:00U:BCLINews ReleaseBrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
2025-04-29 06:30U:BCLINews ReleaseBrainStorm's NurOwn(TM) Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
2025-04-10 07:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn(TM) in ALS
2025-03-31 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
2025-03-26 08:15U:BCLINews ReleaseBrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
2025-03-24 07:00U:BCLINews ReleaseBrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
2024-12-30 08:00U:BCLINews ReleaseBrainStorm Issues 2024 Letter to Shareholders
2024-12-09 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
2024-12-03 07:00U:BCLINews ReleaseBrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
2024-12-02 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
2024-11-14 16:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-11 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn(TM) Phase 3b Trial Manufacturing